1. Home
  2. IOVA vs SPNT Comparison

IOVA vs SPNT Comparison

Compare IOVA & SPNT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • IOVA
  • SPNT
  • Stock Information
  • Founded
  • IOVA 2007
  • SPNT 2011
  • Country
  • IOVA United States
  • SPNT Bermuda
  • Employees
  • IOVA N/A
  • SPNT N/A
  • Industry
  • IOVA Biotechnology: Biological Products (No Diagnostic Substances)
  • SPNT Property-Casualty Insurers
  • Sector
  • IOVA Health Care
  • SPNT Finance
  • Exchange
  • IOVA Nasdaq
  • SPNT Nasdaq
  • Market Cap
  • IOVA 2.6B
  • SPNT 2.3B
  • IPO Year
  • IOVA N/A
  • SPNT N/A
  • Fundamental
  • Price
  • IOVA $5.91
  • SPNT $14.99
  • Analyst Decision
  • IOVA Strong Buy
  • SPNT
  • Analyst Count
  • IOVA 9
  • SPNT 0
  • Target Price
  • IOVA $23.33
  • SPNT N/A
  • AVG Volume (30 Days)
  • IOVA 9.1M
  • SPNT 808.0K
  • Earning Date
  • IOVA 02-26-2025
  • SPNT 02-18-2025
  • Dividend Yield
  • IOVA N/A
  • SPNT N/A
  • EPS Growth
  • IOVA N/A
  • SPNT 31.47
  • EPS
  • IOVA N/A
  • SPNT 1.60
  • Revenue
  • IOVA $90,858,000.00
  • SPNT $2,614,600,000.00
  • Revenue This Year
  • IOVA $13,758.71
  • SPNT N/A
  • Revenue Next Year
  • IOVA $171.20
  • SPNT N/A
  • P/E Ratio
  • IOVA N/A
  • SPNT $9.37
  • Revenue Growth
  • IOVA 12751.20
  • SPNT N/A
  • 52 Week Low
  • IOVA $5.62
  • SPNT $10.98
  • 52 Week High
  • IOVA $18.33
  • SPNT $16.50
  • Technical
  • Relative Strength Index (RSI)
  • IOVA 28.87
  • SPNT 51.16
  • Support Level
  • IOVA $5.62
  • SPNT $14.23
  • Resistance Level
  • IOVA $6.44
  • SPNT $15.81
  • Average True Range (ATR)
  • IOVA 0.45
  • SPNT 0.51
  • MACD
  • IOVA -0.10
  • SPNT -0.01
  • Stochastic Oscillator
  • IOVA 11.46
  • SPNT 40.78

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.

About SPNT SiriusPoint Ltd.

SiriusPoint Ltd provides property and casualty reinsurance coverage to insurance and reinsurance companies in the United States, Canada, Bermuda, the United Kingdom, and Europe. The company operates through two operating segments: Reinsurance and Insurance & Services. The company's product portfolio consists of reinsurance contracts for property insurance including both residential and commercial properties, workers' compensation, personal automobile, businesses' general liability insurance, professional liability insurance to protect professional advisors and service providers, agriculture insurance, and mortgage insurance. The majority of the revenue is generated from its Insurance & Services segment.

Share on Social Networks: